The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention.
Clin Cardiol
; 31(3 Suppl 1): I17-20, 2008 Mar.
Article
em En
| MEDLINE
| ID: mdl-18481817
Platelets play a central role in the atherosclerotic inflammatory response, thrombotic vascular occlusion, microembolization, vasoconstriction, and plaque progression. Persistent platelet activation poses a serious problem among patients with acute coronary syndromes (ACS) and those who have undergone percutaneous coronary intervention (PCI), placing them at risk for ischemic events and subacute stent thrombosis. Patients undergoing PCI are at risk for further ischemic events because of procedure-related platelet activation as well as the inherent persistent platelet hyperreactivity and enhanced thrombin generation associated with ACS. Persistent platelet activation following an acute coronary event and/or PCI supports incorporating antiplatelet strategies into the standard medical management of such patients. In this clinical setting, antiplatelet therapies are capable of improving outcomes. Aspirin, thienopyridines, and glycoprotein IIb/IIIa inhibitors, the 3 major pharmacologic approaches to persistent platelet activation, target various levels of the hemostatic pathways and thrombus formation.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Trombose
/
Inibidores da Agregação Plaquetária
/
Angioplastia Coronária com Balão
/
Ativação Plaquetária
/
Síndrome Coronariana Aguda
Tipo de estudo:
Etiology_studies
Limite:
Humans
Idioma:
En
Revista:
Clin Cardiol
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Estados Unidos
País de publicação:
Estados Unidos